Last reviewed · How we verify
NCT04118179
New Strategy to Predict Early Sepsis
trial testing Blood sample collection in Sepsis in 1,000 participants. Status unknown.
31 July 2023
Quick facts
| Lead sponsor | University of British Columbia |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 1 August 2018 |
| Primary completion | 31 July 2023 |
| Estimated completion | 31 July 2023 |
| Sites | 5 locations across Colombia, Netherlands, Canada, Australia, United States |
Drugs / interventions tested
- Blood sample collection — full drug profile →
Conditions studied
- Sepsis — all drugs for Sepsis →
Sponsor
University of British Columbia
Who can join
19 and older, any sex, with Sepsis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an observational prospective multicentre study on patients attending the emergency department and suspected to have sepsis. Blood markers characteristic of a Cellular Reprogramming (CR) signature and predicting severe sepsis and organ failure will be measured and validated.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04118179
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Blood sample collection
Trials testing the same drug.
- NCT07243067 — Tumor-Derived Extracellular Vesicles for Noninvasive Molecular Classification of Kidney Cancer · not yet recruiting
- NCT07499921 — Clinical and BIOgical Analyses of RECtal Tumors · NA · not yet recruiting
- NCT07516392 — Study of a Polygenic Risk Score to Predict the Risk of Pancreatic Ductal Adenocarcinoma · NA · not yet recruiting
- NCT07455136 — A Study to Develop a Blood-based Test for Aiding the Diagnosis/Prognosis of Traumatic Brain Injury in Adults and for Mon · recruiting
- NCT07063719 — Identification of Cellular Biomarkers of Rare Eye Diseases in Adults · NA · not yet recruiting
Other recruiting trials for Sepsis
Currently open trials in the same condition.
- NCT07507877 — Infraclavicular Axillary Vein Collapsibility Index as a Predictor of Fluid Responsiveness · recruiting
- NCT07154615 — Assessing Immune Dysfunction in Sepsis · recruiting
- NCT07419802 — OxiCLEAR (Oxiris Cytokines and Endotoxin Adsorption Rate) Study · recruiting
- NCT07351344 — African Survey on Sepsis Knowledge (ASK) · recruiting
- NCT07448805 — Accuracy and Safety of the Syai Tag System for Continuous Glucose Monitoring in Intensive Internal Care Unit · NA · recruiting
Other University of British Columbia trials
Trials by the same sponsor.
- NCT07340970 — Sensory Stimuli During Cesarean Delivery · not yet recruiting
- NCT07481201 — Phenylalanine Requirements in the Menstrual Phases · NA · not yet recruiting
- NCT07492095 — Leucine Requirements in School-Age Children · NA · not yet recruiting
- NCT07429305 — Combined Tibial Nerve Stimulation and Standing for People With SCI · NA · recruiting
- NCT07519928 — Exploring the Feasibility and Benefits of Implementing Pelvic Floor Muscle Training During Inpatient Rehabilitation for · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04118179 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of British Columbia
- Last refreshed: 5 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04118179.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing